TL;DR
This study investigates the effectiveness of dual antiplatelet therapy (DAPT) in reducing stroke risk for patients experiencing transient ischemic attacks (TIAs). They found that DAPT significantly lowers the risk of stroke within 90 days, but only for those TIAs identified as high-risk by diffusion-weighted imaging (DWI), suggesting imaging is a crucial factor in treatment decisions.
What Problem Does This Paper Address?
Transient Ischemic Attacks (TIAs), often called "mini-strokes," are warning signs of a potential full stroke. Clinicians use risk stratification tools, like the ABCD2 score, to identify high-risk TIA patients who might benefit from more aggressive treatment, such as dual antiplatelet therapy (DAPT), which combines aspirin and clopidogrel. However, these clinical scores have limitations, and some studies suggest that neuroimaging findings are better predictors of recurrent events. Specifically, diffusion-weighted imaging (DWI) can detect acute ischemic lesions, indicating a higher risk of stroke. This paper addresses the question of whether DAPT is beneficial for TIA patients identified as high-risk specifically by the presence of acute lesions on DWI, a group that might not always be captured by traditional clinical scores.
Methods
The researchers conducted a prospective observational study using data from a TIA database at the First Affiliated Hospital of Zhengzhou University. They enrolled 661 TIA patients who presented within 72 hours of symptom onset. The primary outcome measured was ischemic stroke occurring within 90 days of the TIA.
Key methodological aspects include:
- Patient Cohort: Patients were selected from a prospective, ongoing hospital-based registry.
- DWI Assessment: Patients were categorized into "DWI positive" (showing acute ischemic lesions) and "DWI negative" based on specific imaging criteria.
- Treatment Groups: Patients were divided into those receiving DAPT (clopidogrel + aspirin) and those receiving monotherapy (clopidogrel or aspirin alone) during hospitalization.
- Statistical Analysis: A Cox proportional hazards model was used to analyze the relationship between DAPT and stroke risk, adjusting for potential confounding factors. Kaplan-Meier curves were used to visualize stroke-free survival.
Datasets
The study utilized data from the prospective TIA database of the First Affiliated Hospital of Zhengzhou University, collected between October 2010 and June 2015. This is a real-world clinical dataset, not a newly created benchmark.
Key Insights and Ideas
- Imaging Overrides Clinical Scores: The study strongly suggests that DWI findings are a critical determinant of stroke risk and treatment benefit, potentially more so than traditional clinical scores like ABCD2. The Kappa test indicated poor agreement between ABCD2 score and DWI positivity, highlighting their distinct predictive capabilities.
- DAPT Efficacy is Subgroup-Specific: The most significant finding is that DAPT's benefit in reducing stroke risk is confined to patients with positive DWI. This implies that simply having a high clinical risk score (like ABCD2 ≥ 4) might not be sufficient to warrant DAPT; the presence of actual ischemic changes on DWI is a key indicator.
- Early Intervention Matters: The study emphasizes the importance of early DAPT initiation (within 72 hours of onset) for this high-risk DWI-positive group.
- No Benefit in DWI-Negative Group: Conversely, the study found no statistically significant benefit of DAPT in reducing stroke risk for patients with negative DWI, even if they had a high ABCD2 score.
Key Results
- A total of 661 TIA patients were analyzed, with 279 (42.2%) having positive DWI.
- Among patients with positive DWI, the 90-day stroke risk was significantly lower in the DAPT group (13.4%) compared to the monotherapy group (23.7%) (p = 0.029).
- DAPT was associated with a reduced stroke risk in TIA patients with positive DWI, with a hazard ratio (HR) of 0.54 (95% CI, 0.30-0.97; p = 0.037) after multivariate adjustment.
- In contrast, for patients with negative DWI, DAPT did not show a statistically significant benefit in reducing stroke risk (HR = 0.43; 95% CI, 0.14-1.33; p = 0.142).
- No major adverse events like hemorrhagic stroke were reported.
Limitations and Future Work
The authors acknowledge several limitations:
- Observational Study Design: As an observational study, it cannot definitively prove causation, and there's a possibility of unmeasured confounding factors.
- DAPT Management Complexity: The definition of DAPT management was simplified, and real-world clinical practice can be more flexible, potentially introducing bias.
- DAPT Duration: The duration of DAPT use after hospital discharge was not standardized and could influence outcomes.
- Selection Bias: Being a single-center study, there's a potential for selection bias.
The authors suggest that further multi-center studies are needed to confirm these findings. They also highlight the need for randomized controlled trials to further support the evidence for DAPT benefits, particularly for patients defined by tissue-based criteria (like DWI positivity). The findings provide a "proof of concept" for the utility of DAPT in real-world scenarios for imaging-identified high-risk TIA patients.
Summary updated